Improving treatment for severe lung and blood infections
Advancing Precision Medicine for ARDS and Sepsis
This study is looking at how to better treat patients with serious lung and blood infections by figuring out their unique body responses, so doctors can give the right treatment to help them recover faster.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11034816 on NIH RePORTER |
What this research studies
This research focuses on understanding and treating acute respiratory distress syndrome (ARDS) and sepsis, two serious conditions that often lead to death in critically ill patients. By identifying different molecular phenotypes of these conditions, the research aims to tailor treatments based on individual patient characteristics, which could lead to better outcomes. The approach involves analyzing clinical data and plasma protein biomarkers to distinguish between patients who are hyperinflammatory and those who are hypoinflammatory, allowing for more effective therapeutic interventions. The goal is to develop a new paradigm in critical care medicine that enhances patient care and treatment efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are critically ill patients diagnosed with ARDS or sepsis, particularly those exhibiting hyperinflammatory or hypoinflammatory phenotypes.
Not a fit: Patients with ARDS or sepsis who do not meet the criteria for the identified phenotypes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment outcomes for patients suffering from ARDS and sepsis.
How similar studies have performed: Previous research has shown promise in identifying molecular phenotypes in ARDS and sepsis, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Calfee, Carolyn — University of California, San Francisco
- Study coordinator: Calfee, Carolyn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.